Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation.
Purpose: To retrospectively review post-treatment (post-tx) FDG-PET/CT scans in patients with advanced head and neck squamous cell carcinoma (HNSCC) and known p16 status, treated with definitive (chemo)radiation (RT). Methods: A total of 108 eligible patients had N2A or greater HNSCC treated with ch...
| Published in: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 44; no. 6; pp. 988 - 998 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Jun2017
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122598641&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 122598641 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Jun2017 vid: 44 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 122598641 143992592 10.1007/s00259-016-3612-1 122598641 ppf: 988 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation. aug: au: Awan, Musaddiq Lavertu, Pierre Zender, Chad Rezaee, Rod Fowler, Nicole Karapetyan, Lilit Gibson, Michael Wasman, Jay Faulhaber, Peter Machtay, Mitchell Yao, Min affil: Department of Radiation Oncology , Case Western Reserve University and University Hospitals , 11100 Euclid Avenue Cleveland 44114 USA sug: ab: Purpose: To retrospectively review post-treatment (post-tx) FDG-PET/CT scans in patients with advanced head and neck squamous cell carcinoma (HNSCC) and known p16 status, treated with definitive (chemo)radiation (RT). Methods: A total of 108 eligible patients had N2A or greater HNSCC treated with chemoRT from August 1, 2008, to February 28, 2015, with post-tx PET/CT within 6 months after RT. Kaplan-Meier curves, log-rank statistics, and Cox proportional hazards regression were used for statistical analysis. Results: Median follow-up was 2.38 years. Sixty-eight (63.0%) patients had p16+ and 40 (37.0%) had p16− status. Two-year overall survival and recurrence-free survival were 93.4% and 77.8%, respectively. The negative predictive value (NPV) of PET/CT for local recurrence (LR) was 100%. The NPV for regional recurrence (RR) was 96.5% for all patients, 100% for p16+ patients, and 88.5% for p16− patients. The positive predictive value (PPV) of PET/CT for recurrence was 77.3% for all patients, 50.0% for p16+, and 78.6% for p16−. The PPV for LR was 72.7% for all patients, 50.0% for p16+ patients, and 72.7% for p16− patients. The PPV for RR was 50.0% for all patients, 33% for p16+, and 66.6% for p16−. Post-tx PET/CT and p16 status were independent predictors of recurrence-free survival ( p < 0.01). Conclusions: Post-tx PET/CT predicts treatment outcomes in both p16 + and p16− patients, and does so independently of p16 status. P16− patients with negative PET have a 10% risk of nodal recurrence, and closer follow-up in these patients is warranted. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|